Parsaclisib plus ruxolitinib can improve symptoms and spleen volume in certain patients with myelofibrosis. Acalabrutinib with or without obinutuzumab had sustained safety and efficacy in patients with CLL in six years of follow-up. Paula Rodríguez Otero, MD, described an updated analysis of the KarMMa-3 trial presented at the 65th ASH Annual Meeting. Leyla Shune, MD, discusses the import of promising data for ide-cel in multiple myeloma presented at the 2023 ASH Meeting. Dr. Fonseca, of the Mayo Clinic, spoke with Blood Cancers Today about idecabtagene vicleucel in myeloma treatment. Elranatamab yielded deep and durable responses in relapsed or refractory multiple myeloma, even with biweekly dosing. Dara-CVRd was effective as induction therapy prior to and consolidation therapy following AHSCT in ultra-high-risk myeloma. Motixafortide plus G-CSF mobilized significantly more CD34+ hematopoietic stem and progenitor cells versus placebo in MM. DDX3X dysregulation is involved in the progression of CLL by facilitating NOTCH1 mRNA translation Researchers said there was a need for potentially more effective one-time-only treatment options. Dr. Hans Lee met with Blood Cancers Today to discuss outcomes and treatments after triple-class exposure in multiple myeloma. It included 21 patients with lymphoma with a median age of 57 who had received a median of four prior lines of therapy. Dr. Raje shared findings on CAR T-cell therapy in earlier lines of treatment for relapsed or refractory multiple myeloma. Patients with lenalidomide-refractory MM had significant improvements in health-related QoL and symptoms after cilta-cel. Cilta-cel was significantly more cost-effective versus DPd or PVd regimens in relapsed or refractory multiple myeloma. Researchers collected serial peripheral blood mononuclear cell samples from patients with R/R LBCL treated with axi-cel. The study evaluated ROR1 expression levels in a panel of MCL cell lines and primary patient samples. Jeffrey Matous, MD, discusses data from the phase Ib MonumenTAL-2 study on talquetamab plus pomalidomide in multiple myeloma. The phase II, multicenter, single-arm study is assessing axi-cel for frontline treatment in patients with high-risk LBCL. The analysis assessed the impacts of bridging therapy when used in patients receiving axi-cel for large B-cell lymphoma.